Core Insights - MYQORZO™ (aficamten) has been approved by the U.S. FDA for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), aimed at improving functional capacity and symptoms [1][4][5] - The drug is available in multiple dosages (5 mg, 10 mg, 15 mg, and 20 mg) and is a once-daily oral allosteric and reversible inhibitor of cardiac myosin motor activity, which reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction in patients with oHCM [2][17] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [21] - The launch of MYQORZO marks a significant milestone for Cytokinetics, reflecting its commitment to patients and the culmination of extensive scientific and clinical development efforts [3][21] Product Details - MYQORZO is indicated specifically for adults with symptomatic oHCM, and it works by inhibiting cardiac myosin to alleviate symptoms associated with the condition [5][17] - The drug has been engineered for predictable exposure response, rapid onset of action, and reversibility, making it a novel treatment option for patients [17] Clinical and Safety Information - The approval of MYQORZO was based on positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New England Journal of Medicine [4] - Important safety information includes a boxed warning for the risk of heart failure due to reduced left ventricular ejection fraction (LVEF), necessitating regular echocardiogram assessments during treatment [6][9][10] Distribution and Support Programs - MYQORZO is available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program, which includes specific requirements for prescribers, patients, and pharmacies [11][15] - Cytokinetics has established a personalized support program, MYQORZO & You™, to assist patients in navigating their treatment journey and provide education and financial assistance [4][21]

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Cytokinetics, Incorporated regarding possible breaches of fiduciary duties to shareholders [1] Group 1 - Cytokinetics disclosed that the FDA has extended the review period for its cardiac myosin inhibitor drug, aficamten, by three months [1]

PresentationWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Cytokinetics. And presenting on behalf of the company, we have President and CEO, Robert Blum. Robert, over to you.Robert I. BlumCEO, President & Director Thank you, Tessa, and thank you to JPMorgan for inviting us again this year. This is a very important year for Cytokinetics, as I'll be elaborating as we are ...

Cytokinetics Conference Call Summary Company Overview - **Company**: Cytokinetics - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Key Presenters**: Robert Blum (President and CEO), Andrew Callos (Chief Commercial Officer), Fady Malik (Head of R&D), Sung Lee (CFO) [1][2][25] Industry Focus - **Industry**: Biotechnology, specifically focusing on cardiovascular and neuromuscular conditions - **Product**: Mycorrhiza, a treatment for obstructive hypertrophic cardiomyopathy (OHCM) [3][4] Core Points and Arguments 1. **FDA Approval and Launch**: Mycorrhiza has received FDA approval for treating adults with OHCM and is now launched in the U.S. and China, with expected European approval in Q1 [5][6][20] 2. **Commercial Strategy**: Cytokinetics aims to build a specialty cardiology franchise, focusing on high revenue per prescriber and addressing concentrated customer segments [7][8] 3. **Pipeline Development**: Mycorrhiza is part of a broader pipeline that includes treatments for heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) [6][22] 4. **Clinical Data**: Mycorrhiza demonstrated significant improvements in exercise capacity and symptom relief in clinical trials, with a favorable safety profile [9][10] 5. **Market Dynamics**: The company targets approximately 10,000 healthcare professionals who treat the majority of OHCM patients, with a focus on building relationships with key prescribers [11][30] 6. **Sales Force**: A highly experienced sales team has been established, with over 9,000 applicants for 100 positions, emphasizing the importance of a tailored approach to market engagement [12][17] 7. **Pricing Strategy**: Mycorrhiza is priced at a wholesale acquisition cost of $108,400, aiming for parity with existing treatments while focusing on clinical differentiation [18][36] 8. **Payer Mix**: The expected payer mix is approximately 55%-60% Medicare and 30%-35% commercial, with plans to support access through medical exceptions and patient assistance programs [36][37] Additional Important Insights 1. **Patient Engagement**: Cytokinetics emphasizes a unique patient experience through tailored support programs and a one-on-one relationship model with healthcare providers [17][29] 2. **Market Research**: Awareness levels among key prescribers are high, with many waiting for Mycorrhiza's launch to begin prescribing [30][31] 3. **Future Studies**: The ACACIA study, focusing on non-obstructive HCM, is expected to provide additional data that could expand the market opportunity significantly [22][40] 4. **Competitive Landscape**: The company draws parallels with Bristol Myers Squibb's successful launch of Camzyos, indicating a potential for Mycorrhiza to achieve similar or greater market penetration [27][28][39] Conclusion Cytokinetics is positioned to leverage its recent FDA approval of Mycorrhiza to establish a strong foothold in the specialty cardiology market, with a comprehensive strategy that includes a robust pipeline, targeted marketing efforts, and a focus on patient and physician engagement. The upcoming clinical data and market dynamics will be critical in shaping the company's growth trajectory in the coming years [24][48]

1 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics' research and development activities; clinical trial ini ...

Cytokinetics, Incorporated (NASDAQ:CYTK) is a prominent biopharmaceutical company dedicated to the development of innovative treatments based on muscle biology for serious diseases such as heart failure and amyotrophic lateral sclerosis (ALS). Competing in the dynamic biotech industry against giants like Amgen and Biogen, Cytokinetics has recently been in the spotlight due to significant insider trading activity by its Executive Vice President, Andrew Callos.On January 5, 2026, Andrew Callos executed a nota ...

Core Insights - Cytokinetics, Incorporated will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM Pacific Time [1] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [3] - The company’s product MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) by the U.S. FDA and the China National Medical Products Administration [3] - The European Medicines Agency has adopted a positive opinion for MYQORZO™ (aficamten), with a decision from the European Commission expected in Q1 2026 [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction, alongside ongoing pre-clinical research in muscle biology [3]

Core Insights - Tango Therapeutics, Inc. has appointed Mr. Sung Lee to its Board of Directors, bringing over 20 years of finance leadership experience in the biopharmaceutical and technology sectors [1][2] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision cancer medicines [1] - The company is advancing its lead program, vopimetostat, into registrational studies [2] Leadership Appointment - Mr. Sung Lee's experience includes serving as Executive Vice President and Chief Financial Officer at Cytokinetics since May 2024, and prior roles at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics [2] - He has a strong background in corporate strategy, investor relations, and finance, which will support Tango's late-stage clinical development activities [2] Educational Background - Mr. Lee holds a bachelor's degree in economics from the University of California, Irvine, and a Master of Business Taxation from the University of Southern California [2]

Core Viewpoint - Truist Securities has raised its price target on Cytokinetics, Inc. to $84 from $70 while maintaining a Buy rating, reflecting updated forecasts following the regulatory approval of MYQORZO [1] Group 1: Regulatory Approval and Market Potential - The recent approval of MYQORZO, which features a differentiated label, positions it to become a significant revenue driver in obstructive hypertrophic cardiomyopathy (oHCM) [2] - Truist updated its model to estimate worldwide peak sales for MYQORZO in oHCM at $3.7 billion, slightly below the $3.8 billion consensus estimate [2] Group 2: Revenue Projections and Launch Expectations - A steady launch of MYQORZO is expected to begin in early 2026, with performance anticipated to be at least comparable to the launch trajectory of Camzyos [3] - Truist modeled fiscal 2026 aficamten revenue at $106 million, aligning with consensus expectations [3] - Looking ahead, the analyst projects worldwide peak adjusted total revenue of $4.6 billion in 2035, marginally above the $4.5 billion consensus estimate [3]

Core Insights - Cytokinetics Incorporated has received FDA approval for Myqorzo (aficamten), a drug aimed at treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking a significant milestone for the company [1][3][5] - The approval addresses a substantial medical need and aims to improve patients' functional capacity while alleviating symptoms [1][3][5] Financial Summary - Truist Financial has set a price target of $84 for CYTK, indicating a potential upside of approximately 24.76% from its trading price of $67.33 on December 22, 2025 [2][5] - The stock has shown a recent increase to $67.57, reflecting a 7.73% rise or $4.85, with a trading range today between $63.18 and $70.98 [2] - CYTK's market capitalization is approximately $8.04 billion, with a trading volume of 5,494,603 shares on the NASDAQ [4] Market Performance - The stock has experienced volatility, with a 52-week trading range between $29.31 and $70.98, reflecting the market's response to the company's developments and future potential [4][5]